Gladius Capital Management LP Bristol Myers Squibb CO Transaction History

Gladius Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$47.98 - $54.4 $34,881 - $39,548	727 New	727 $39,000
Q2 2022 Aug 10, 2022	SELL	$72.62 - $79.98 $524,171 - $577,295	-7,218 Reduced 83.72%	1,404 $109,000
Q1 2022 Apr 29, 2022	BUY	$61.48 - $73.72 $382,344 - $458,464	6,219 Added 258.8%	8,622 $630,000
Q4 2021 Feb 08, 2022	BUY	$53.63 - $62.52 $128,872 - $150,235	2,403 New	2,403 $150,000
Q2 2021 Aug 06, 2021	SELL	$61.91 - $67.42 $73,425 - $79,960	-1,186 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$59.34 - $66.74 $70,377 - $79,153	1,186 New	1,186 $75,000

2,425

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.